Intranasal drug developer Impel NeuroPharma has announced the appointment of former Allergan VP of External Science & Innovation Ellen A. Lubman as Chief Business Officer. Her previous experience also includes stints at Kadmon Pharmaceuticals and Bristol-Myers Squibb. According to the company, Lubman will head up partnering and acquisition activities.
In August 2018, Impel announced that the first patient had been dosed in a Phase 3 study of INP104 intranasal dihydroergotamine (DHE) for the treatment of migraine and that it had initiated a Phase 1 trial of its INP105 intranasal dry powder olanzapine, which is in development for the treatment of acute agitation in bipolar I disorder and schizophrenia.
Impel NeuroPharma CEO Jon Congleton commented, “We are thrilled to welcome Ellen to Impel at this important time, as we approach multiple upcoming milestones for our pipeline of investigational therapies that leverage our novel Precision Olfactory Delivery, or POD, device technology. Ellen’s diverse business background – ranging from pharmaceutical strategy and business development to royalty structuring and equity investing – makes her the ideal team member to help bring our innovative therapies to patients in the CNS community as rapidly as possible.”
Lubman said, “I am excited for the opportunity to help lead Impel at this critical point in the company’s evolution and believe we have a truly unique and promising technology that will not only bring value to our stakeholders, but will also positively impact the lives of patients living with serious CNS diseases. I look forward to working with Impel’s executive team and board to advance the company through its next phase of growth.”
Read the Impel NeuroPharma press release.
